Squarepoint’s Zevra Therapeutics ZVRA Stock Holding History

Squarepoint’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-176,000	Closed	-$1.32M	–	5167
2025 Q1	$1.32M	Buy	+176,000	New	+$1.4M	﹤0.01%	2425

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's ZVRA Position: Q2 2026 in Review

Squarepoint sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 182,864 shares — an estimated $1.7M sold.

Squarepoint first reported a position in ZVRA in Q1 2021 and held it in 13 quarters. The position peaked at $2.84M in Q4 2025. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Squarepoint reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
Squarepoint sold 182,864 Zevra Therapeutics shares in Q2 2026, an estimated $1.7M.
Squarepoint first reported a position in Zevra Therapeutics in Q1 2021 and held it in 13 quarters.
Squarepoint's Zevra Therapeutics position peaked at $2.84M in Q4 2025.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.